US · BCTX
BriaCell Therapeutics Corp.
- Sector
- Healthcare · Biotechnology
- Headquarters
- West Vancouver, BC V7T 2X1
- Website
- briacell.com
Price · as of 2025-07-31
$4.18
Market cap 7.2M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | $684.04 | ||||
| 2013 | $293.16 | ||||
| 2014 | $390.88 | ||||
| 2015 | $660.00 | ||||
| 2016 | $450.00 | ||||
| 2017 | $330.00 | ||||
| 2018 | $270.00 | ||||
| 2019 | $90.00 | ||||
| 2020 | $43.10 | ||||
| 2021 | $72.40 | ||||
| 2022 | $59.50 | ||||
| 2023 | $58.00 | ||||
| 2024 | $9.90 | ||||
| 2025 | $12.40 |
AI valuation
Our deep-learning model estimates BriaCell Therapeutics Corp.'s (BCTX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $4.18
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| BCTX | BriaCell Therapeutics Cor… | $4.18 | 7.2M | — | — | — | — | -0.64 | 0.95 | — | 0.03 | -1.44 | 0.96 | 0.00% | — | — | -343.04% | 1683.01% | -192.49% | 0.00 | -735.71 | 5.01 | 4.63 | 0.39 | 4450.00% | — | 1632.00% | -167.26% | -7.14 | 1742.76% | 0.00% | 0.00% | 56.64% | 0.03 | 0.03 | — | -8.16 |
| ALLR | Allarity Therapeutics, In… | $0.97 | 15.6M | — | — | — | — | -0.07 | 0.14 | — | 0.68 | — | 0.14 | 0.00% | — | — | -541.17% | 671.53% | -142.07% | 0.11 | -41.72 | 2.06 | 2.01 | 0.75 | -9974.00% | — | 3849.00% | -1036.16% | -1.60 | 441.86% | 0.00% | 0.00% | 1339.49% | 0.60 | 0.93 | — | -10.62 |
| ASBP | Aspire Biopharma Holdings… | $1.39 | 4.81M | — | — | — | — | -866.02 | -736.56 | — | -97.51 | — | -736.56 | 0.00% | — | — | -14.52% | -32.00% | -13.01% | -0.82 | 3.46 | 0.09 | 0.02 | -0.11 | -76087.00% | — | -5940.00% | -0.02% | -0.16 | -2.75% | 0.00% | 0.00% | 1.21% | -367.68 | -4282.42 | — | 295.56 |
| CRIS | Curis, Inc. | $1.14 | 15.61M | +342% | +2% | — | — | -0.42 | -3.06 | 1.68 | -0.03 | — | -1.23 | 99.10% | -408.34% | -397.77% | -634.71% | 156.53% | -73.20% | -0.49 | -72.43 | 1.39 | 1.23 | 0.40 | -2321.00% | 883.00% | 294.00% | -215.59% | -2.08 | 139.03% | 0.00% | 0.00% | 0.00% | -0.03 | -0.03 | 0.12 | -44.91 |
| CTXR | Citius Pharmaceuticals, I… | $0.74 | 8.27M | — | — | — | — | -0.33 | 0.19 | — | -0.28 | — | -0.38 | 0.00% | — | — | -57.75% | -58.28% | -32.10% | 0.03 | -143.87 | 0.62 | 0.09 | 0.06 | -4338.00% | — | -585.00% | -203.36% | -0.59 | -40.17% | 0.00% | 0.00% | 0.00% | -0.28 | -0.40 | — | -3.53 |
| ENTO | Entero Therapeutics, Inc. | $2.85 | 13.58M | — | — | — | — | -0.43 | 0.13 | — | -491.36 | — | 0.14 | 0.00% | — | — | -58.82% | -0.05% | -39.13% | 0.00 | — | 3.03 | 0.01 | 1.47 | -8880.00% | — | -2842.00% | -119.84% | -0.33 | -31.51% | 0.00% | 0.00% | 0.00% | -490.90 | -0.83 | — | -2.37 |
| HOTH | Hoth Therapeutics, Inc. | $1.01 | 13.39M | — | — | — | — | -0.85 | 1.01 | — | -2.17 | — | 1.01 | 0.00% | — | — | -99.75% | -9559.27% | -91.21% | 0.00 | — | 9.20 | 8.52 | -258.29 | -4435.00% | — | -1739.00% | -100.42% | -8.40 | -8119.72% | 0.00% | 0.00% | 0.00% | 0.01 | 0.01 | — | -8.42 |
| LPTX | Leap Therapeutics, Inc. | $0.62 | 25.83M | — | — | — | — | -0.24 | 0.47 | — | 0.46 | — | 0.47 | 0.00% | — | — | -141.94% | 631.86% | -110.79% | 0.01 | — | 3.41 | 3.41 | 0.70 | -5452.00% | — | 3782.00% | -365.79% | -4.28 | 543.85% | 1.42% | -0.30% | 1.42% | 0.44 | 0.51 | — | -16.49 |
| MBRX | Moleculin Biotech, Inc. | $2.39 | 2.89M | — | — | — | — | -0.18 | 0.64 | — | 0.00 | — | -0.75 | 0.00% | — | — | -135.80% | -1009.89% | -78.93% | 0.08 | — | 0.97 | 0.80 | 0.14 | -5806.00% | — | -144.00% | -619.14% | -4.45 | -905.04% | 0.00% | 0.00% | 0.00% | 0.00 | 0.00 | — | -17.68 |
| PALI | Palisade Bio, Inc. | $1.77 | 263.74M | +38% | — | — | — | -0.08 | 0.16 | — | 0.59 | — | 0.16 | 0.00% | — | — | -153.55% | 1021.24% | -115.82% | 0.02 | -1238.25 | 3.24 | 3.04 | 0.67 | -6227.00% | -10000.00% | 948.00% | -1013.04% | -3.77 | 838.01% | 0.00% | 0.00% | 0.00% | 0.57 | 0.69 | — | -20.99 |
| PCSA | Processa Pharmaceuticals,… | $2.17 | 4.92M | — | — | — | — | -0.12 | 0.87 | — | -0.03 | — | 0.87 | 0.00% | — | — | -354.51% | -2381.97% | -262.87% | 0.04 | — | 1.22 | 0.78 | 0.09 | -5436.00% | — | 3945.00% | -761.08% | -7.34 | -2223.27% | 0.00% | 0.00% | 1.08% | -0.03 | -0.03 | — | -49.42 |
About BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.
- CEO
- William V. Williams
- Employees
- 16
- Beta
- 2.03
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $4.18) − 1 = — (DCF, example).